Parexel International,  a leading global biopharmaceutical services organisation, has been named the 2014 Best Performing CRO in Taiwan for its innovative drug development strategies and healthcare industry leadership. Parexel received the award in May from the Foundation of Medical Professionals Alliance in Taiwan (FMPAT) during the Taiwan Biotechnology Trend and Challenges conference.

“Parexel applies its scientific expertise and innovative approaches to reducing clinical trial complexity to help create greater opportunities for clinical research in Taiwan and across the region,” said Albert Liou, Parexel vice chairman, Asia Pacific. “We appreciate this recognition of our ongoing commitment to simplifying  drug development for our customers and supporting their efforts to prevent and cure disease.”

Since 1999, Parexel has provided drug developers in Taiwan with a broad range of clinical research and consulting services, as well as innovative technology solutions. Two years ago, the Company formed an alliance with National Taiwan University Hospital to strengthen its ability to meet customer demand for end-to-end services in this rapidly growing market.

“Parexel has a strong presence to support both international, multi-centre trials that include APAC as well as region and country-specific needs,” said Mark A. Goldberg, M.D., president and chief operating officer, Parexel. “With 4,400 employees in 23 locations across 12 countries in the region, Parexel offers an unparalleled infrastructure to support customers across the entire development continuum.”

Founded in 1992, FMPAT has united medical and health professionals, and devoted itself to the promotion of health and dignity of society and citizens in Taiwan. The foundation is a pioneer in clinical research training programmes, medical ethics and related policy advocacy.